Compare Sanofi SA (SNY) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Under Armour Inc Class A — how do they compare? Sanofi SA trades at $40.07 (market cap $95.18B), while Under Armour Inc Class A trades at $4.93 (market cap $2.07B). The key difference: Sanofi SA is far larger — about 46× Under Armour Inc Class A's market cap, and Sanofi SA pays a 6.01% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Under Armour Inc Class A for 99 Days on average.
| SNY | UAA | |
|---|---|---|
Market Cap | $95.18B | $2.07B |
Volume | 2,995,646 | 12,050,442 |
Sector | Health | Consumer Cyclical |
52-Week High | $52.34 | $8.14 |
52-Week Low | $39.51 | $4.17 |
Typical Hold Time | 94 Days | 99 Days |
Enterprise Value | $114.48B | $3.05B |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.23, showing minimal daily movement with a 0.07% gain. The stock presents mixed signals with bearish technical indicators but strong fundamental performance, including three consecutive quarterly earnings beats. Recent expansion of the immunology alliance with Regeneron through an $8 billion deal highlights strategic growth initiatives. Valuation metrics show a P/E of 22.14 and P/S of 1.77, while profitability remains solid with a 72.77% gross margin.
SNY offers steady growth potential driven by pipeline expansion and Dupixent momentum, though patent expiration risks loom. Analyst sentiment is cautiously optimistic with 44% buy ratings, but technical weakness and projected 2026 earnings decline present near-term headwinds. The stock represents a balanced opportunity for long-term investors seeking pharmaceutical exposure with manageable risk.
Under Armour (UAA) trades at $4.88, up 1.24% with a mixed technical outlook showing bullish moving averages but neutral oscillators. The company faces fundamental challenges with negative net income margins (-9.99%) and ROE (-29.82%) despite beating Q2 2026 EPS estimates. Recent news highlights the company's brand transformation efforts amid softer demand, with management maintaining profitability outlook despite revenue cuts.
The stock presents a high-risk opportunity with analyst consensus pointing to 18.6% upside to the $5.79 price target. Key risks include persistent revenue weakness, negative cash flow trends, and competitive pressures. The 27% buy rating suggests cautious optimism, but investors need clear evidence of sustainable margin improvement and revenue stabilization for meaningful upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
